Sandoz Group AG (SDZXF)

36.07 0.00 (0.00%) At close: 10:51AM EDT

Sandoz Group AG

Forum 1
Novartis Campus
Basel 4056
Switzerland
41 61 324 11 11
https://www.sandoz.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 22,633

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Richard Saynor	Chief Executive Officer	N/A	N/A	1967
Mr. Colin Michael Bond	Chief Financial Officer	N/A	N/A	1960
Mr. Asaf Gal	Chief Technology Officer	N/A	N/A	1969
Ms. Claire D'Abreu-Hayling	Chief Scientific Officer	N/A	N/A	1964
Ms. Karen M. King	Head Global Investor Relations	N/A	N/A	N/A
Ms. Ingrid Sollerer	General Counsel & Chief Compliance Officer	N/A	N/A	1974
Ms. Tripti Jha	Chief People Officer	N/A	N/A	1977
Mr. Francisco Ballester	President of International	N/A	N/A	1961
Mr. Pierre Bourdage	Chief Commercial Officer	N/A	N/A	1979
Dr. Glenn A. Gerecke Ph.D.	Chief Manufacturing & Supply Officer	N/A	N/A	1959

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

Corporate governance

Sandoz Group AG’s ISS governance QualityScore as of 1 June 2024 is 3. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.